{"title":"探讨中药在提高经皮冠状动脉介入治疗效果中的补充作用：机制、益处和未来的研究方向。","authors":"Sidao Zheng, Jun Guo, Qi Wang","doi":"10.2147/TCRM.S511630","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Percutaneous coronary intervention (PCI) is a cornerstone treatment for coronary artery disease (CAD), yet opportunities remain to improve clinical outcomes, symptom management, and long-term prognosis. Traditional Chinese Medicine (TCM), with its multi-target and multi-pathway mechanisms, offers a promising complementary approach to enhance PCI efficacy.</p><p><strong>Methods: </strong>A systematic search was conducted in PubMed and Web of Science using the terms: (\"Percutaneous Coronary Intervention\" AND \"Traditional Chinese Medicine\") and (\"Percutaneous Coronary Intervention\" AND \"Chinese Herbal Drugs\"). Randomized controlled trials (RCTs) with ≥100 participants were included to evaluate TCM's clinical efficacy in PCI. Pharmacological studies were also reviewed to explore underlying mechanisms.</p><p><strong>Results: </strong>A review of 20 RCTs showed that TCM plays multiple roles in CAD treatment during PCI. Specific interventions such as Danhong Injection, Tongxinluo Capsule, and Shenzhu Guanxin Granule were found to alleviate angina symptoms, restore cardiac function, reduce cardiac biomarkers, prevent no-reflow/slow-flow phenomena, inhibit in-stent restenosis, and improve prognosis while reducing complications. Mechanistically, TCM exerts its effects through antiplatelet action, anti-inflammation, inhibition of smooth muscle proliferation, vasodilation, microcirculation improvement, and endothelial protection.</p><p><strong>Conclusion: </strong>This systematic review highlights the complementary benefits of TCM in PCI for CAD patients. Effective interventions such as Danhong Injection and Tongxinluo Capsule contribute to symptom relief, cardiac function restoration, restenosis inhibition, and prognosis improvement. These benefits are linked to TCM's multi-target mechanisms, including anti-inflammatory and antiplatelet effects. Future high-quality studies are needed to further validate these findings and refine clinical applications.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"21 ","pages":"1069-1083"},"PeriodicalIF":2.8000,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12260233/pdf/","citationCount":"0","resultStr":"{\"title\":\"Exploring the Complementary Role of Traditional Chinese Medicine in Enhancing Percutaneous Coronary Intervention Outcomes: Mechanisms, Benefits, and Future Research Directions.\",\"authors\":\"Sidao Zheng, Jun Guo, Qi Wang\",\"doi\":\"10.2147/TCRM.S511630\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Percutaneous coronary intervention (PCI) is a cornerstone treatment for coronary artery disease (CAD), yet opportunities remain to improve clinical outcomes, symptom management, and long-term prognosis. Traditional Chinese Medicine (TCM), with its multi-target and multi-pathway mechanisms, offers a promising complementary approach to enhance PCI efficacy.</p><p><strong>Methods: </strong>A systematic search was conducted in PubMed and Web of Science using the terms: (\\\"Percutaneous Coronary Intervention\\\" AND \\\"Traditional Chinese Medicine\\\") and (\\\"Percutaneous Coronary Intervention\\\" AND \\\"Chinese Herbal Drugs\\\"). Randomized controlled trials (RCTs) with ≥100 participants were included to evaluate TCM's clinical efficacy in PCI. Pharmacological studies were also reviewed to explore underlying mechanisms.</p><p><strong>Results: </strong>A review of 20 RCTs showed that TCM plays multiple roles in CAD treatment during PCI. Specific interventions such as Danhong Injection, Tongxinluo Capsule, and Shenzhu Guanxin Granule were found to alleviate angina symptoms, restore cardiac function, reduce cardiac biomarkers, prevent no-reflow/slow-flow phenomena, inhibit in-stent restenosis, and improve prognosis while reducing complications. Mechanistically, TCM exerts its effects through antiplatelet action, anti-inflammation, inhibition of smooth muscle proliferation, vasodilation, microcirculation improvement, and endothelial protection.</p><p><strong>Conclusion: </strong>This systematic review highlights the complementary benefits of TCM in PCI for CAD patients. Effective interventions such as Danhong Injection and Tongxinluo Capsule contribute to symptom relief, cardiac function restoration, restenosis inhibition, and prognosis improvement. These benefits are linked to TCM's multi-target mechanisms, including anti-inflammatory and antiplatelet effects. Future high-quality studies are needed to further validate these findings and refine clinical applications.</p>\",\"PeriodicalId\":22977,\"journal\":{\"name\":\"Therapeutics and Clinical Risk Management\",\"volume\":\"21 \",\"pages\":\"1069-1083\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-07-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12260233/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutics and Clinical Risk Management\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/TCRM.S511630\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutics and Clinical Risk Management","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/TCRM.S511630","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
摘要
背景：经皮冠状动脉介入治疗（PCI）是冠状动脉疾病（CAD）的基础治疗方法，但仍有机会改善临床结果、症状管理和长期预后。中药多靶点、多通路的作用机制为提高PCI疗效提供了一种很有前景的补充途径。方法：系统检索PubMed和Web of Science，检索词为：（经皮冠状动脉介入治疗）和（经皮冠状动脉介入治疗）和（中草药）。纳入≥100人的随机对照试验（rct），评价中药在PCI中的临床疗效。药理学研究也进行了回顾，以探讨潜在的机制。结果：对20项随机对照试验的回顾显示，中药在PCI期间CAD治疗中发挥了多种作用。特异性干预如丹红注射液、通心络胶囊、肾珠冠心颗粒等可缓解心绞痛症状，恢复心功能，降低心脏生物标志物，预防无回流/慢流现象，抑制支架内再狭窄，改善预后，减少并发症。从机制上讲，中药通过抗血小板、抗炎症、抑制平滑肌增殖、舒张血管、改善微循环、保护内皮等发挥作用。结论：本系统综述强调了中医药在冠心病患者PCI治疗中的互补益处。丹红注射液、通心络胶囊等有效干预措施可缓解症状，恢复心功能，抑制再狭窄，改善预后。这些益处与中药的多靶点机制有关，包括抗炎和抗血小板作用。未来需要高质量的研究来进一步验证这些发现并完善临床应用。
Exploring the Complementary Role of Traditional Chinese Medicine in Enhancing Percutaneous Coronary Intervention Outcomes: Mechanisms, Benefits, and Future Research Directions.
Background: Percutaneous coronary intervention (PCI) is a cornerstone treatment for coronary artery disease (CAD), yet opportunities remain to improve clinical outcomes, symptom management, and long-term prognosis. Traditional Chinese Medicine (TCM), with its multi-target and multi-pathway mechanisms, offers a promising complementary approach to enhance PCI efficacy.
Methods: A systematic search was conducted in PubMed and Web of Science using the terms: ("Percutaneous Coronary Intervention" AND "Traditional Chinese Medicine") and ("Percutaneous Coronary Intervention" AND "Chinese Herbal Drugs"). Randomized controlled trials (RCTs) with ≥100 participants were included to evaluate TCM's clinical efficacy in PCI. Pharmacological studies were also reviewed to explore underlying mechanisms.
Results: A review of 20 RCTs showed that TCM plays multiple roles in CAD treatment during PCI. Specific interventions such as Danhong Injection, Tongxinluo Capsule, and Shenzhu Guanxin Granule were found to alleviate angina symptoms, restore cardiac function, reduce cardiac biomarkers, prevent no-reflow/slow-flow phenomena, inhibit in-stent restenosis, and improve prognosis while reducing complications. Mechanistically, TCM exerts its effects through antiplatelet action, anti-inflammation, inhibition of smooth muscle proliferation, vasodilation, microcirculation improvement, and endothelial protection.
Conclusion: This systematic review highlights the complementary benefits of TCM in PCI for CAD patients. Effective interventions such as Danhong Injection and Tongxinluo Capsule contribute to symptom relief, cardiac function restoration, restenosis inhibition, and prognosis improvement. These benefits are linked to TCM's multi-target mechanisms, including anti-inflammatory and antiplatelet effects. Future high-quality studies are needed to further validate these findings and refine clinical applications.
期刊介绍：
Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines, therapeutic and surgical interventions in all clinical areas.
The journal welcomes submissions covering original research, clinical and epidemiological studies, reviews, guidelines, expert opinion and commentary. The journal will consider case reports but only if they make a valuable and original contribution to the literature.
As of 18th March 2019, Therapeutics and Clinical Risk Management will no longer consider meta-analyses for publication.
The journal does not accept study protocols, animal-based or cell line-based studies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
